Hipertensión arterial en la enfermedad renal crónica

  1. Arroyo, D.
  2. Quiroga, B.
  3. de la Fuente, G. de Arriba
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Año de publicación: 2019

Título del ejemplar: Enfermedades nefrourinarias (III) Hipertensión y enfermedades vasculares renales

Serie: 12

Número: 81

Páginas: 4772-4778

Tipo: Artículo

DOI: 10.1016/J.MED.2019.06.003 DIALNET GOOGLE SCHOLAR

Otras publicaciones en: Medicine: Programa de Formación Médica Continuada Acreditado

Resumen

A common comorbidity of chronic renal failure (CRF) is arterial hypertension (AHT), and it is both cause and consequence of CRF. Multiple and interrelated mechanisms are involved in AHT including hydrosaline retention, stimulation of the renin-angiotensin-aldosterone system (RAAS) and hyperactivity of the sympathetic nervous system. Diagnosis requires an accurate blood pressure measurement (BP) in medical consultancy. There is increasing evidence of the advantages of ambulatory BP monitoring and 24-hours BP measurement. Low-sodium diet is the mainstay of non-pharmacological management of AHT. In patients with proteinuria RAAS blockers are the antihypertensive drugs of choice, being mandatory to assess their side effects. In general terms, 130-139/70-79mm Hg is the goal in BP treatment, however it has to be individualized according to the patient comorbidities and the presence or not of diabetes.

Referencias bibliográficas

  • Agarwal R, Sinha AD, Pappas MK, Ammous F. Chlorthalidone for poorly controlled hypertension in chronic kidney disease: an interventional pilot study. Am J Nephrol. 2014;39(2):171-82.
  • Agarwal R. Blood pressure components and the risk for end stage renal disease and death in chronic kidney disease. Clin J Am Soc Nephrol. 2009;4(4):830-7.
  • Arroyo D, Betriu A, Martínez-Alonso M, Vidal T, Valdivielso JM, Fernández E. Observational multicenter study to evaluate the prevalence and prognosis of subclinical atheromatosis in a Spanish chronic kidney disease cohort: baseline data from the NEFRONA study. BMC Nephrol. 2014;15:168.
  • Bakris GL, Weir MR, Secic M, Campbell B, Weis-McNulty A. Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int. 2004;65(6):1991-2002.
  • Banegas JR, Ruilope LM, de la Sierra A, Vinyoles E, Gorostidi M, de la Cruz JJ. Relationship between clinic and ambulatory blood pressure measurements and mortality. New Eng J Med. 2018;378(16):1509-20.
  • Bargman JM, Skorecki K. Nefropatía crónica. Harrison Principios de Medicina Interna. 18ª ed. China: Mc Graw Hill; 2012. p. 2308-21.
  • Boyle SM, Berns JS. Erythropoietin and resistant hypertension in CKD. Semin Nephrol. 2014;34(5):540-9
  • Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001; 345(12):861-9.
  • Buter H, Hemmelder MH, Navis G, de Jong PE, de Zeeuw D. The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. Nephrol Dial Transplant. 1998;13(7):1682-5.
  • Chang AR, Lóser M, Malhotra R, Appel LJ. Blood pressure goals in patients with chronic kidney disase: A review of evidence and guidelines. Clin J Am Soc Nephrol. 2019;14(1):161-9.
  • Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1575-85.
  • Elliot WJ, Peixoto AJ, Bakris JL. Primary and secondary hypertension. Brenner & Rector’s The Kidney. 10ª ed. Philadelphia: Elsevier; 20
  • Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA. 2015;313(6):603-15. 16. p. 1522-66.
  • Fernández Juarez G, Luño J, Barrio V, de Vinuesa SG, Praga M, Goicoechea M. Effect of dual blockade of the renin angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial. Am J Kidney Dis. 2013;61(2):211-8.
  • Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013;369(20):1892-903.
  • Hamrahian SM, Falkner B. Hypertension in chronic kidney disease. Ad-vExp Med Biol. 2017;956:307-25.
  • Hermida RC, Ayala DE, Mojón A, Fernández JR. Bedtime dosing of antihypertensive medications reduces cardiovascular risk in CKD. J Am SocNephrol. 2011;22(12):2313-21.
  • Herrington WG, Preiss D, Haynes R, von Eynatten M, Staplin N, HauskeSJ. The potential for improving cardiorenal outcomes by sodium glucose cotransporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study. Clin Kidney J. 2018;11(6):749-61.
  • Horowitz B, Miskulin D, Zager P. Epidemiology of hypertension in CKD. Adv Chronic Kidney Dis. 2015;22(2):88-95.
  • Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int Suppl. 2012;2:337-414.
  • Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med. 1994;330(13):877-84.
  • Klein IH, Ligtenberg G, Neumann J, Oey PL, Koomans HA, Blankestijn PJ. Sympathetic nerve activity is inappropriately increased in chronic re-nal disease. J Am Soc Nephrol. 2003;14(12):3239-44.
  • Kotchen TA. Vasculopatía hipertensiva. En: Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J. Harrison Principios de Medicina Interna. 18ª ed. China: Mc Graw Hill; 2012. p. 2042-59.
  • Kovesdy CP. Hypertension in chronic kidney disease after the Systolic Blood Pressure Intervention Trial: targets, treatment and current uncertainties. Nephrol Dial Transplant. 2017;32Suppl2:ii219-ii23.
  • Ku E, Glidden DV, Johansen KL, Sarnak M, Tighiouart H, Grimes B. Association between strict blood pressure control during chronic kidney disease and lower mortality after onset of end stage renal disease. Kidney Int. 2015;87(5):1055-60.
  • Ku E, Gassman J, Appel LJ, Smogorzewski M, Sarnak MJ, Glidden DV. BP control and long term risk of ESRD and mortality. J Am Soc Nephrol. 2017;28(2):671-7.
  • Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med. 2008;148(1):30-48.
  • Lambers Heerspink HJ, Holtkamp FA, Parving HH, Navis GJ, Lewis JB, Ritz E. Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers. Kidney Int. 2012;82(3):330-7.
  • Malhotra R, Craven T, Ambrosius WT, Killeen AA, Haley WE, Cheung AK,. Effects of intensive blood pressure lowering on kidney tubule injury in CKD: A longitudinal subgroup analysis in SPRINT. Am J Kid-ney Dis. 2019;73(1):21-30.
  • Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA. Liraglutide and cardiovascular outcomes in type 2 dia-betes. N Engl J Med. 2016;375(4):311-22.
  • Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ. Executive summary: heart disease and stroke statistics : 2016 update: a report from the American Heart Association. Circu-lation. 2016;133(4):447-54.
  • Muntner P, Anderson A, Charleston J, Chen Z, Ford V, Makos G. Hypertension awareness, treatment, and control in adults with CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis. 2010;55(3):441-51.
  • Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N. Canagliflozin and cardiovascular and renal Events in type 2 diabetes. N Engl J Med. 2017;377(7):644-57.
  • Obi Y, Kalantar-Zadeh K, Shintani A, Kovesdy CP, Hamano T. Estimated glomerular filtration rate and the risk benefit profile of intensive blood pressure control amongst nondiabetic patients: a post hoc analysis of a randomized clinical trial. J Intern Med. 2018;283(3):314-27.
  • Panizo N, Goicoechea M, García de Vinuesa S, Arroyo D, Yuste C, Rincón A. Chronic kidney disease progression in patients with autosomal dominant polycystic kidney disease. Nefrologia. 2012;32(2): 197-205.
  • Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN. Recommendations for blood pressure measurement in humans and experimental animals: Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension. 2005;45(1):142-61.
  • Pogue V, Rahman M, Lipkowitz M, Toto R, Miller E, Faulkner M. Disparate estimates of hypertension control from ambulatory and clinic blood pressure measurements in hypertensive kidney disease. Hyperten-sion. 2009;53(1):20-7.
  • Pohl MA, Blumenthal S, Cordonnier DJ, De Alvaro F, Deferrari G, Eisner G. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. J Am Soc Nephrol. 2005;16(10):3027-37.
  • Poulter NR, Savopoulos C, Anjum A, Apostolopoulou M, Chapman N, Cross M. Randomized crossover trial of the impact of morning or evening dosing of antihypertensive agents on 24-hour ambulatory blood pressure. Hypertension. 2018;72(4):870-3.
  • Raine AE, Bedford L, Simpson AW, Ashley CC, Brown R, Woodhead JS. Hyperparathyroidism, platelet intracellular free calcium and hypertension in chronic renal failure. Kidney Int. 1993;43(3):700-5.
  • Rossignol P, Massy ZA, Azizi M, Bakris G, Ritz E, Covic A. The double challenge of resistant hypertension and chronic kidney disease. Lancet. 2015;386(10003):1588-98.
  • Ruggenenti P, Perna A, Loriga G, Ganeva M, EneIordache B, Turturro M. Blood pressure control for renoprotection in patients with nondiabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet. 2005;365(9463):939-46.
  • Saran R, Padilla RL, Gillespie BW, Heung M, Hummel SL, Derebail VK. A randomized crossover trial of dietary sodium restriction in stage 3-4 CKD. Clin J Am Soc Nephrol. 2017;12(3):399-407.
  • Schrier RW, Abebe KZ, Perrone RD, Torres VE, Braun WE, Steinman TI. Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med. 2014;371(24):2255-66.
  • Slagman MC, Waanders F, Hemmelder MH, Woittiez AJ, Janssen WM, Lambers Heerspink HJ. Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial. BMJ. 2011;343:d4366.
  • Thomas G, Drawz PE. BP measurement techniques: what they mean for patients with kidney disease. Clin J Am Soc Nephrol. 2018;13(7):1124-31.
  • Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C. 2017 guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018 Jun;71(6):1269-324.
  • Williams B, Mancia G, Spiering W, AgabitiRosei E, Azizi M, Burnier M. 2018 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). Blood Press. 2018;27(6):314-40.
  • Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, Mc-Innes G. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386(10008):2059-68.
  • Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347-57.
  • Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288(19):2421-31.
  • Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM. A randomized trial of intensive versus standard blood pressure control. N Engl J Med. 2015;373(22): 2103-16.
  • Yusuf S, Teo KK, Pogue J, Dyal L, Copland I Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547-59.
  • Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-28.
Fuente de los datos: Dialnet